Literature DB >> 12496147

Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective.

Weiwen Jiang1, Henry J Baker, Bruce F Smith.   

Abstract

The mucosal delivery of antigens requires an effective adjuvant to induce mucosal immunity. Current mucosal adjuvants include cholera toxin (CT) and Escherichia coli heat-labile toxin. Unmethylated CpG immunostimulatory oligodeoxynucleotides (ODNs) have been proposed as novel mucosal adjuvants. In this study, mice were immunized with sonicated Helicobacter felis with CT and/or CpG ODN adjuvants. All groups receiving either adjuvant singly or in combination developed increased serum anti-H. felis immunoglobulin G (IgG). The addition of either CpG or CT, or both, produced a specific fecal anti-H. felis IgA response, with the highest IgA levels occurring in animals immunized intranasally with sonicated H. felis with CT and CpG. Following H. felis challenge, addition of the adjuvant CpG ODN provided no significant protection, while groups given CT showed a high degree of protection, although not complete. When CpG ODN was combined with CT and the vaccine combination was delivered intranasally, no bacterial colonization was detected by quantitative PCR, providing "sterile immunity" and demonstrating synergy between CpG ODN and CT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496147      PMCID: PMC143171          DOI: 10.1128/IAI.71.1.40-46.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

Review 1.  CpG DNA as a Th1 trigger.

Authors:  K Heeg; S Zimmermann
Journal:  Int Arch Allergy Immunol       Date:  2000-02       Impact factor: 2.749

Review 2.  CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function.

Authors:  R S Chu; D Askew; C V Harding
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

3.  CpG DNA is an effective oral adjuvant to protein antigens in mice.

Authors:  M J McCluskie; R D Weeratna; A M Krieg; H L Davis
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

Review 4.  Toll-like receptors; their physiological role and signal transduction system.

Authors:  O Takeuchi; S Akira
Journal:  Int Immunopharmacol       Date:  2001-04       Impact factor: 4.932

5.  Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients.

Authors:  A M Caliendo; K St George; S Y Kao; J Allega; B H Tan; R LaFontaine; L Bui; C R Rinaldo
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

6.  Quantitative real-time PCR for Porphyromonas gingivalis and total bacteria.

Authors:  S R Lyons; A L Griffen; E J Leys
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

7.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.

Authors:  S Bauer; C J Kirschning; H Häcker; V Redecke; S Hausmann; S Akira; H Wagner; G B Lipford
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

8.  Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.

Authors:  W S Gallichan; R N Woolstencroft; T Guarasci; M J McCluskie; H L Davis; K L Rosenthal
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

9.  Type I Helicobacter pylori lipopolysaccharide stimulates toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells.

Authors:  T Kawahara; S Teshima; A Oka; T Sugiyama; K Kishi; K Rokutan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

10.  CpG motifs in bacterial DNA trigger direct B-cell activation.

Authors:  A M Krieg; A K Yi; S Matson; T J Waldschmidt; G A Bishop; R Teasdale; G A Koretzky; D M Klinman
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

View more
  7 in total

1.  The use of CpG as an adjuvant to Toxoplasma gondii vaccination.

Authors:  Jennifer A Spencer; Bruce F Smith; Anthony J Guarino; Byron L Blagburn; Henry J Baker
Journal:  Parasitol Res       Date:  2004-01-15       Impact factor: 2.289

2.  Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Authors:  Alba E Sanchez; Guillermo Aquino; Pedro Ostoa-Saloma; Juan P Laclette; Leticia Rocha-Zavaleta
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

3.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

Review 4.  Vaccinating against Helicobacter pylori in the developing world.

Authors:  Shamila Zawahir; Steven J Czinn; John G Nedrud; Thomas G Blanchard
Journal:  Gut Microbes       Date:  2013-11-06

Review 5.  Role of Toll-like receptors in Helicobacter pylori infection and immunity.

Authors:  Sinéad M Smith
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 6.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Authors:  Hidekazu Shirota; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2013-11-26       Impact factor: 5.217

7.  Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination.

Authors:  Iris Bosschem; Jagadeesh Bayry; Ellen De Bruyne; Kim Van Deun; Annemieke Smet; Griet Vercauteren; Richard Ducatelle; Freddy Haesebrouck; Bram Flahou
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.